ADAPTIVE BIOTECHNOLOGIES CORP
NASDAQ: ADPT (Adaptive Biotechnologies Corpor)
Last update: 9 hours ago11.80
0.32 (2.79%)
| Previous Close | 11.48 |
| Open | 11.90 |
| Volume | 1,018,695 |
| Avg. Volume (3M) | 2,276,206 |
| Market Cap | 1,792,620,544 |
| Price / Sales | 8.96 |
| Price / Book | 9.16 |
| 52 Weeks Range | |
| Earnings Date | 31 Jul 2025 |
| Profit Margin | -74.84% |
| Operating Margin (TTM) | -56.45% |
| Diluted EPS (TTM) | -0.950 |
| Quarterly Revenue Growth (YOY) | 25.20% |
| Total Debt/Equity (MRQ) | 115.90% |
| Current Ratio (MRQ) | 2.92 |
| Operating Cash Flow (TTM) | -85.34 M |
| Levered Free Cash Flow (TTM) | -21.40 M |
| Return on Assets (TTM) | -15.05% |
| Return on Equity (TTM) | -61.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Adaptive Biotechnologies Corpor | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | -1.5 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.00 |
|
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 2.35% |
| % Held by Institutions | 98.36% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Aristotle Atlantic Partners, Llc | 31 Mar 2025 | 2,941,212 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Craig-Hallum, 27.12%) | Buy |
| Median | 11.50 (-2.54%) | |
| Low | 9.00 (Morgan Stanley, -23.73%) | Hold |
| Average | 11.75 (-0.42%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 9.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Craig-Hallum | 18 Jun 2025 | 15.00 (27.12%) | Buy | 10.47 |
| Piper Sandler | 06 May 2025 | 13.00 (10.17%) | Buy | 8.81 |
| Morgan Stanley | 05 May 2025 | 9.00 (-23.73%) | Hold | 10.03 |
| Goldman Sachs | 02 May 2025 | 10.00 (-15.25%) | Buy | 9.84 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Jul 2025 | Announcement | Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR® |
| 03 Jun 2025 | Announcement | Grindr Appoints Veteran Public Company CFO and Audit Committee Chair Chad Cohen to Board of Directors |
| 30 May 2025 | Announcement | Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers |
| 28 May 2025 | Announcement | Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference |
| 01 May 2025 | Announcement | Adaptive Biotechnologies Reports First Quarter 2025 Financial Results |
| 10 Apr 2025 | Announcement | Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025 |
| 08 Apr 2025 | Announcement | Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |